Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.44−1.12 (-3.92%)
Close on Nov 16, 2026Market cap $4.76BP/E –Yield –
Cogent Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Cogent Biosciences's enterprise value was $4.25B on Nov 11, 2026, against $5.28B a year earlier. Over the last 5 years it ranged from $18.92M to $5.78B, with a median of $611.40M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.25B | -7.9% |
| 2025 | Dec 31, 2025 | $4.62B | +778.2% |
| 2024 | Dec 31, 2024 | $526.06M | +131.4% |
| 2023 | Dec 29, 2023 | $227.37M | -56.0% |
| 2022 | Dec 30, 2022 | $517.21M | +275.4% |
| 2021 | Dec 31, 2021 | $137.78M | – |
| 2020 | Dec 31, 2020 | -$10.77M | – |
| 2019 | Dec 31, 2019 | -$25.05M | -130.9% |
| 2018 | Dec 31, 2018 | $81.12M | – |
See a number that looks wrong?